Z. Younossi, F. Tacke, M. Arrese, B. C. Sharma, I. Mostafa et al., Global Perspectives on Nonalcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis, Hepatology, 2018.

, Disponible sur

Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry et al., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, vol.64, issue.1, pp.73-84, 2016.

Z. Younossi, Q. M. Anstee, M. Marietti, T. Hardy, L. Henry et al., Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nature Reviews Gastroenterology & Hepatology, vol.15, issue.1, pp.11-20, 2017.

M. Rinella and M. Charlton, The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health: Editorial, Hepatology. juill, vol.64, issue.1, pp.19-22, 2016.

. Lonardo, 2017 -Nonalcoholic fatty liver disease Evolving paradig

F. Barrera and J. George, The role of diet and nutritional intervention for the management of patients with NAFLD, Clin Liver Dis. févr, vol.18, issue.1, pp.91-112, 2014.

L. Gerber, M. Otgonsuren, A. Mishra, C. Escheik, A. Birerdinc et al., Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study, Aliment Pharmacol Ther, vol.36, issue.8, pp.772-81, 2012.

Y. Liu, G. L. Patman, J. Leathart, A. Piguet, A. D. Burt et al., Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma, J Hepatol. juill, vol.61, issue.1, pp.75-81, 2014.

P. Dongiovanni, S. Petta, C. Maglio, A. L. Fracanzani, R. Pipitone et al., Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease, Hepatology. févr, vol.61, issue.2, pp.506-520, 2015.

K. G. Alberti and P. Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med. juill, vol.15, issue.7, pp.539-53, 1998.

, Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults, Adult Treatment Panel III)

, JAMA. 16 mai, vol.285, pp.2486-97, 2001.

K. Alberti, P. Zimmet, and J. Shaw, The metabolic syndrome--a new worldwide definition, Lancet. 24 sept, vol.366, issue.9491, pp.1059-62, 2005.

K. G. Alberti, H. Robert, G. Scott, M. , Z. Paul et al., Harmonizing the Metabolic Syndrome, Circulation, vol.120, issue.16, pp.1640-1645, 2009.

N. Chalasani, Z. Younossi, J. E. Lavine, M. Charlton, K. Cusi et al., The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the, Hepatology, vol.67, issue.1, pp.328-57, 2018.

S. Organización-mundial-de-la, Geneva: World Health Organization, Department of Mental Health and Substance Abuse, Global status report on alcohol, 2004.

D. E. Kleiner, E. M. Brunt, M. V. Natta, C. Behling, M. J. Contos et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, vol.41, issue.6, pp.1313-1334, 2005.

R. Pais, C. F. Fedchuk, L. Bedossa, P. Lebray, P. Poynard et al., A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver, Journal of Hepatology. 1 sept, vol.59, issue.3, pp.550-556, 2013.

S. Mcpherson, T. Hardy, E. Henderson, A. D. Burt, C. P. Day et al., Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management, Journal of Hepatology. 1 mai, vol.62, issue.5, pp.1148-55, 2015.

S. Singh, A. M. Allen, Z. Wang, L. J. Prokop, M. H. Murad et al., Fibrosis Progression in Nonalcoholic Fatty Liver versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies, Clin Gastroenterol Hepatol. avr, vol.13, issue.4, pp.643-654, 2015.

Z. M. Younossi, M. Stepanova, N. Rafiq, H. Makhlouf, Z. Younoszai et al., Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality, Hepatology. juin, vol.53, issue.6, pp.1874-82, 2011.

L. A. Adams, Q. M. Anstee, H. Tilg, and G. Targher, Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases, Gut. 1 juin, vol.66, issue.6, pp.1138-53, 2017.

A. E. Morrison, F. Zaccardi, K. Khunti, and M. J. Davies, Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis, Liver International

N. Rafiq, C. Bai, Y. Fang, M. Srishord, A. Mccullough et al., Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver, Clinical Gastroenterology and Hepatology. 1 févr, vol.7, issue.2, pp.234-242, 2009.

M. J. Armstrong, L. A. Adams, A. Canbay, and W. Syn, Extrahepatic complications of nonalcoholic fatty liver disease, Hepatology, vol.59, issue.3, pp.1174-97, 2014.

G. Kim, H. C. Lee, J. Choe, M. Kim, M. J. Lee et al., Association between non-alcoholic fatty liver disease and cancer incidence rate, Journal of Hepatology. 1 janv, vol.68, issue.1, pp.140-146, 2018.

S. B. Hicks, K. Mara, J. J. Larson, T. M. Therneau, D. Allen et al., The Incidence of Extrahepatic Malignancies in Nonalcoholic Fatty Liver Disease (NAFLD), p.1

. Easl-easd-easo, Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, Journal of Hepatology. juin, vol.64, issue.6, pp.1388-402, 2016.

G. Marchesini and M. Babini, Nonalcoholic fatty liver disease and the metabolic syndrome, Minerva Cardioangiol. avr, vol.54, issue.2, pp.229-268, 2006.

P. Angulo, D. E. Kleiner, S. Dam-larsen, L. A. Adams, E. S. Bjornsson et al., Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology. août, vol.149, issue.2, pp.389-397, 2015.

M. Ekstedt, H. Hagström, P. Nasr, M. Fredrikson, P. Stål et al., Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology. mai, vol.61, issue.5, pp.1547-54, 2015.

P. S. Dulai, S. Singh, J. Patel, M. Soni, L. J. Prokop et al., Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis, Hepatology. mai, vol.65, issue.5, pp.1557-65, 2017.

N. H. Afdhal and D. Nunes, Evaluation of liver fibrosis: a concise review, Am J Gastroenterol. juin, vol.99, issue.6, pp.1160-74, 2004.

E. M. Brunt, C. G. Janney, D. Bisceglie, A. M. Neuschwander-tetri, B. A. Bacon et al., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, The American Journal of Gastroenterology. 1 sept, vol.94, issue.9, pp.2467-74, 1999.

R. Juluri, R. Vuppalanchi, J. Olson, A. Ünalp, M. L. Van-natta et al., Generalizability of the NASH CRN Histological Scoring System for Nonalcoholic Fatty Liver Disease, J Clin Gastroenterol. janv, vol.45, issue.1, pp.55-63, 2011.

F. Piccinino, E. Sagnelli, G. Pasquale, and G. Giusti, Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies, J Hepatol, vol.2, issue.2, pp.165-73, 1986.

V. Ratziu, C. F. Heurtier, A. Gombert, S. Giral, P. Bruckert et al., Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology. juin, vol.128, issue.7, pp.1898-906, 2005.

A. Regev, E. G. Molina, and K. R. Reddy, Sampling Error and Intraobserver Variation in Liver Biopsy in Patients With Chronic HCV Infection, Nature Reviews Gastroenterology & Hepatology, vol.97, issue.10, p.5, 2002.

M. Demir, S. Lang, D. Nierhoff, U. Drebber, A. Hardt et al., Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease, J Clin Gastroenterol. sept, vol.47, issue.8, pp.719-745, 2013.

G. Musso, R. Gambino, M. Cassader, and G. Pagano, Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Annals of Medicine. 1 déc, vol.43, issue.8, pp.617-666, 2011.

S. Petta, V. Wong, C. Cammà, J. Hiriart, G. Wong et al., Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD, Alimentary Pharmacology & Therapeutics, vol.46, issue.6, pp.617-644, 2017.

P. Angulo, J. M. Hui, G. Marchesini, E. Bugianesi, J. George et al., The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, vol.45, issue.4, pp.846-54, 2007.

A. G. Shah, A. Lydecker, K. Murray, B. N. Tetri, M. J. Contos et al., USE OF THE FIB4 INDEX FOR NON-INVASIVE EVALUATION OF FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE, Clin Gastroenterol Hepatol, vol.7, issue.10, pp.1104-1116, 2009.

R. K. Sterling, E. Lissen, N. Clumeck, R. Sola, M. C. Correa et al., Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology. juin, vol.43, issue.6, pp.1317-1342, 2006.

. Easl-aleh, Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis, Journal of Hepatology. 1 juill, vol.63, issue.1, pp.237-64, 2015.

P. Calès, F. Oberti, S. Michalak, I. Hubert-fouchard, M. Rousselet et al., A novel panel of blood markers to assess the degree of liver fibrosis, Hepatology. déc, vol.42, issue.6, pp.1373-81, 2005.

J. Boursier, J. Vergniol, A. Guillet, J. Hiriart, A. Lannes et al., Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease, Journal of Hepatology. sept, vol.65, issue.3, pp.570-578, 2016.

F. Imbert-bismut, V. Ratziu, L. Pieroni, C. F. Benhamou, Y. Poynard et al., Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study, The Lancet. 7 avr, vol.357, issue.9262, pp.1069-75, 2001.

G. Lassailly, R. Caiazzo, A. Hollebecque, D. Buob, E. Leteurtre et al., Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity, Eur J Gastroenterol Hepatol. juin, vol.23, issue.6, pp.499-506, 2011.

T. H. Lee, S. H. Han, J. D. Yang, D. Kim, and M. Ahmed, Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score, Gut Liver. mai, vol.7, issue.3, pp.323-331, 2013.

S. A. Harrison, D. Oliver, H. L. Arnold, S. Gogia, and B. A. Neuschwander-tetri, Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease, Gut, vol.57, issue.10, pp.1441-1448, 2008.

C. Wai, J. K. Greenson, R. J. Fontana, J. D. Kalbfleisch, J. A. Marrero et al., A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology. août, vol.38, issue.2, pp.518-544, 2003.

S. Mcpherson, S. F. Stewart, E. Henderson, A. D. Burt, and C. P. Day, Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease, Gut. 1 sept, vol.59, issue.9, pp.1265-1274, 2010.

J. Hiriart and V. De-le, Non-invasive methods for liver fibrosis assessment, vol.24, p.15, 2019.

V. Wong, J. Vergniol, G. Wong, J. Foucher, H. Chan et al., Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease, Hepatology, vol.51, issue.2, pp.454-62, 2010.

V. Wong, J. Vergniol, G. Wong, J. Foucher, A. Chan et al., Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease, American Journal of Gastroenterology. déc, vol.107, issue.12, pp.1862-71, 2012.

S. Gaia, S. Carenzi, A. L. Barilli, E. Bugianesi, A. Smedile et al., Reliability of transient elastography for the detection of fibrosis in Non-Alcoholic Fatty Liver Disease and chronic viral hepatitis, Journal of Hepatology. 1 janv, vol.54, issue.1, pp.64-71, 2011.

M. Yoneda, M. Yoneda, H. Mawatari, K. Fujita, H. Endo et al., Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD), Digestive and Liver Disease. 1 mai, vol.40, issue.5, pp.371-379, 2008.

S. Petta, V. D. Marco, C. Cammà, G. Butera, D. Cabibi et al., Reliability of liver stiffness measurement in nonalcoholic fatty liver disease: the effects of body mass index, Alimentary Pharmacology & Therapeutics, vol.33, issue.12, pp.1350-60, 2011.

K. Das, R. Sarkar, S. M. Ahmed, A. R. Mridha, P. S. Mukherjee et al., Normal" liver stiffness measure (LSM) values are higher in both lean and obese individuals: A population-based study from a developing country, Hepatology, vol.55, issue.2, pp.584-93, 2012.

V. De-lédinghen, V. Wong, J. Vergniol, G. Wong, J. Foucher et al., Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®, Journal of Hepatology. 1 avr, vol.56, issue.4, pp.833-842, 2012.

G. Wong, J. Vergniol, P. Lo, W. Wong, V. Foucher et al., Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe, Ann Hepatol. août, vol.12, issue.4, pp.570-80, 2013.

E. Durango, C. Dietrich, H. K. Seitz, C. U. Kunz, G. T. Pomier-layrargues et al., Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients, Hepat Med, vol.5, pp.43-52, 2013.

R. P. Myers, G. Pomier-layrargues, R. Kirsch, A. Pollett, A. Duarte-rojo et al., Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients, Hepatology. janv, vol.55, issue.1, pp.199-208, 2012.

V. De-lédinghen, J. Vergniol, J. Foucher, F. El-hajbi, W. Merrouche et al., Feasibility of liver transient elastography with FibroScan using a new probe for obese patients, Liver Int. août, vol.30, issue.7, pp.1043-1051, 2010.

S. Petta, V. Wong, C. Cammà, J. Hiriart, G. Wong et al., Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values, Hepatology, vol.65, issue.4, pp.1145-55, 2017.

C. F. Dietrich, J. Bamber, A. Berzigotti, S. Bota, V. Cantisani et al., EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, 2017.

, Ultraschall Med. août, vol.38, issue.4, pp.377-94, 2017.

C. C. Park, P. Nguyen, C. Hernandez, R. Bettencourt, K. Ramirez et al., Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease, Gastroenterology. févr, vol.152, issue.3, pp.598-607, 2017.

G. Xiao, S. Zhu, X. X. Yan, L. Yang, J. Wu et al., Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis, Hepatology, vol.66, issue.5, pp.1486-501, 2017.

H. Hagström, P. Nasr, M. Ekstedt, U. Hammar, P. Stål et al., Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, Journal of Hepatology. 1 déc, vol.67, issue.6, pp.1265-73, 2017.

J. Pang, S. Zimmer, S. Niu, P. Crotty, J. Tracey et al., Liver Stiffness by Transient Elastography Predicts Liver-Related Complications and Mortality in Patients with Chronic Liver Disease, PLoS One, vol.9, issue.4

M. A. Robic, B. Procopet, S. Métivier, J. M. Péron, J. Selves et al., Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: A prospective study, Journal of Hepatology, vol.55, issue.5, pp.1017-1041, 2011.

S. Singh, L. L. Fujii, M. H. Murad, Z. Wang, S. K. Asrani et al., Liver Stiffness Is Associated With Risk of Decompensation, Liver Cancer, and Death in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol. déc, vol.11, issue.12, pp.1573-89, 2013.

J. Vergniol, J. Foucher, E. Terrebonne, P. Bernard, . Bail-b-le et al., Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C, Gastroenterology. 1 juin, vol.140, issue.7, pp.1970-1979, 2011.

. Lédinghen-v-de, J. Vergniol, C. Barthe, J. Foucher, F. Chermak et al., Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus, Alimentary Pharmacology & Therapeutics, vol.37, issue.10, pp.979-88, 2013.

. Angulo-p, . Bugianesi-e, C. P. Bjornsson-es, . Mills-pr, and . Barrera-f, Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.145, issue.4, pp.782-791, 2013.

D. Kim, W. R. Kim, H. J. Kim, and T. M. Therneau, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology. 1 avr, vol.57, issue.4, pp.1357-65, 2013.

N. Peleg, S. Arbib, O. Issachar, A. Cohen-naftaly, M. Braun et al., Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. Vespasiani-Gentilucci U, éditeur, PLOS ONE. 14 août, vol.13, issue.8, p.202393, 2018.

S. Shili, G. Wong, H. Jean-baptiste, K. Liu, F. Chermak et al., Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease, Journal of Hepatology -Abstract congrès EASL 2019. 1 avr, vol.70, issue.1, p.761, 2019.

S. U. Kim, D. Song, J. H. Heo, J. Yoo, B. K. Kim et al., Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke, Atherosclerosis. 1 mai, vol.260, pp.156-62, 2017.

S. C. You, K. J. Kim, S. U. Kim, B. K. Kim, J. Y. Park et al., Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification, Journal of Gastroenterology and Hepatology, vol.30, issue.10, pp.1536-1578, 2015.

S. Dogan, M. Celikbilek, Y. K. Yilmaz, S. Sarikaya, G. Zararsiz et al., Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease, European Journal of Gastroenterology & Hepatology. mars, vol.27, issue.3, pp.298-304, 2015.

D. Ralph, B. Vasan-ramachandran, S. , P. Michael, J. et al., General Cardiovascular Risk Profile for Use in Primary Care, Circulation. 12 févr, vol.117, issue.6, pp.743-53, 2008.

A. J. Taylor, J. Bindeman, I. Feuerstein, F. Cao, M. Brazaitis et al., Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project, J Am Coll Cardiol. 6 sept, vol.46, issue.5, pp.807-821, 2005.

W. J. Howard, Assessment of Coronary Artery Disease by Cardiac Computed Tomography: A Scientific Statement From the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology, Yearbook of Endocrinology. janv, pp.91-93, 2007.

M. J. Pletcher, J. A. Tice, M. Pignone, and W. S. Browner, Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events: A Systematic Review and Meta-analysis, Archives of Internal Medicine. 28 juin, vol.164, issue.12, p.1285, 2004.

H. Völzke, D. M. Robinson, V. Kleine, R. Deutscher, W. Hoffmann et al., Hepatic steatosis is associated with an increased risk of carotid atherosclerosis, World J Gastroenterol. 28 mars, vol.11, issue.12, pp.1848-53, 2005.

M. Ekstedt, L. E. Franzén, U. L. Mathiesen, L. Thorelius, M. Holmqvist et al., Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology, vol.44, issue.4, pp.865-73, 2006.

R. Lautamäki, R. Borra, P. Iozzo, M. Komu, T. Lehtimäki et al., Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes, Am J Physiol Endocrinol Metab. août, vol.291, issue.2, pp.282-290, 2006.

G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari et al., Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients, Diabetes Care. 1 mai, vol.30, issue.5, pp.1212-1220, 2007.

G. Perseghin, G. Lattuada, D. Cobelli, F. Esposito, A. Belloni et al., Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver, Hepatology. janv, vol.47, issue.1, pp.51-59, 2008.

S. Sookoian and C. J. Pirola, Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review, Journal of Hepatology, vol.49, issue.4, pp.600-607, 2008.

K. Lau, R. Lorbeer, R. Haring, C. O. Schmidt, H. Wallaschofski et al., The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study, J Hypertens. sept, vol.28, issue.9, pp.1829-1864, 2010.

V. Wong, G. Wong, G. Yip, A. Lo, J. Limquiaco et al., Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease, Gut. 1 déc, vol.60, issue.12, pp.1721-1728, 2011.

M. Stepanova and Z. M. Younossi, Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population, Clinical Gastroenterology and Hepatology. 1 juin, vol.10, issue.6, pp.646-50, 2012.

K. Sung, S. H. Wild, H. J. Kwag, and C. D. Byrne, Fatty Liver, Insulin Resistance, and Features of Metabolic Syndrome. Diabetes Care, vol.35, pp.2359-64, 2012.

E. T. Oni, A. S. Agatston, M. J. Blaha, J. Fialkow, R. Cury et al., A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care? Atherosclerosis, vol.230, pp.258-67, 2013.

D. Kim, S. Choi, E. H. Park, W. Lee, J. H. Kang et al., Nonalcoholic Fatty Liver Disease is Associated with Coronary Artery Calcification, Disponible sur, vol.56

L. Pacifico, D. Martino, M. , D. Merulis, A. Bezzi et al., Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease, Hepatology. févr, vol.59, issue.2, pp.461-70, 2014.

A. Arulanandan, B. Ang, R. Bettencourt, J. Hooker, C. Behling et al., Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis, Clinical Gastroenterology and Hepatology. août, vol.13, issue.8, pp.1513-1520, 2015.

Y. Chen, M. Xu, T. Wang, J. Sun, W. Sun et al., Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease, Atherosclerosis. 1 juill, vol.241, issue.1, pp.145-50, 2015.

A. Mantovani, M. Pernigo, C. Bergamini, S. Bonapace, P. Lipari et al., Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes, PLoS ONE, vol.10, issue.8, p.135329, 2015.

C. D. Byrne and G. Targher, NAFLD: A multisystem disease, Journal of Hepatology. avr, vol.62, issue.1, pp.47-64, 2015.

R. Gerald, Insulin Resistance and Coronary Heart Disease in Nondiabetic Individuals

T. Arteriosclerosis and V. Biology, , vol.32, pp.1754-1763, 2012.

M. R. Salazar, H. A. Carbajal, W. G. Espeche, M. Aizpurúa, L. Sisnieguez et al., Insulin resistance: The linchpin between prediabetes and cardiovascular disease, Diabetes and Vascular Disease Research. mars, vol.13, issue.2, pp.157-63, 2016.

V. Ormazabal, S. Nair, O. Elfeky, C. Aguayo, C. Salomon et al., Association between insulin resistance and the development of cardiovascular disease, New England Journal of Medicine. 18 sept, vol.17, issue.12, pp.1131-1172, 2014.

I. Idris, S. Gray, and R. Donnelly, Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes, Diabetologia. 1 mai, vol.44, issue.6, pp.659-73, 2001.

L. P. Bharath, T. Ruan, Y. Li, A. Ravindran, X. Wan et al., Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo, Diabetes. nov, vol.64, issue.11, pp.3914-3940, 2015.

M. K. Jensen, T. M. Bartz, K. J. Mukamal, L. Djoussé, J. R. Kizer et al., Fetuin-A, Type 2 Diabetes, and Risk of Cardiovascular Disease in Older Adults, Diabetes Care. mai, vol.36, issue.5, pp.1222-1230, 2013.

G. A. Laughlin, K. Cummins, C. L. Wassel, L. B. Daniels, and J. H. Ix, THE ASSOCIATION OF FETUIN-A WITH CARDIOVASCULAR DISEASE MORTALITY IN OLDER COMMUNITY-DWELLING ADULTS: THE RANCHO BERNARDO STUDY, J Am Coll Cardiol. 8 mai, vol.59, issue.19, pp.1688-96, 2012.

R. Meex and M. J. Watt, Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance, Nature Reviews Endocrinology. 9 juin, vol.13, issue.9, pp.509-529, 2017.

T. Kadowaki and T. Yamauchi, Adiponectin and adiponectin receptors, Endocr Rev. mai, vol.26, issue.3, pp.439-51, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00174540

S. Li, H. J. Shin, E. L. Ding, and R. M. Van-dam, Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis, JAMA. 8 juill, vol.302, issue.2, pp.179-88, 2009.

J. Kokkinos, S. Tang, K. Rye, and K. L. Ong, The role of fibroblast growth factor 21 in atherosclerosis, Atherosclerosis. 1 févr, vol.257, pp.259-65, 2017.

A. Mutanen, P. Heikkilä, J. Lohi, T. Raivio, H. Jalanko et al., Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure, J Hepatol. janv, vol.60, issue.1, pp.183-90, 2014.

F. Bonnet and . La-nash-augmente-t-elle-le-risque-cardiovasculaire, Médecine des Maladies Métaboliques. 1 déc, vol.11, issue.8, pp.692-698, 2017.

S. Romeo, J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox et al., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nature Genetics. déc, vol.40, issue.12, pp.1461-1466, 2008.

L. Valenti, A. Al-serri, A. K. Daly, E. Galmozzi, R. Rametta et al., Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, Hepatology. avr, vol.51, issue.4, pp.1209-1226, 2010.

A. Lonardo, S. Ballestri, and G. Targher, Not all forms of NAFLD were created equal". Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?, Atherosclerosis. 1 févr, vol.257, pp.253-258, 2017.

J. Kozlitina, E. Smagris, S. Stender, B. G. Nordestgaard, H. H. Zhou et al., Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease, Nature Genetics. avr, vol.46, issue.4, pp.352-358, 2014.

Y. Liu, H. L. Reeves, A. D. Burt, D. Tiniakos, S. Mcpherson et al., TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease, Nat Commun. 30 juin, vol.5, p.4309, 2014.

O. L. Holmen, H. Zhang, Y. Fan, D. H. Hovelson, E. M. Schmidt et al., Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk, Nature Genetics. avr, vol.46, issue.4, pp.345-51, 2014.

B. Kahali, Y. Liu, A. K. Daly, C. P. Day, Q. M. Anstee et al., TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?, Gastroenterology. 1 avr, vol.148, issue.4, pp.679-84, 2015.

T. Hardy, M. Zeybel, C. P. Day, C. Dipper, S. Masson et al., Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease, Gut, vol.66, issue.7, pp.1321-1329, 2017.

J. Ma, S. Hwang, A. Pedley, J. M. Massaro, U. Hoffmann et al., Bidirectional relationship between fatty liver and cardiovascular disease risk factors, J Hepatol. févr, vol.66, issue.2, pp.390-397, 2017.

C. D. Williams, J. Stengel, M. I. Asike, D. M. Torres, J. Shaw et al., Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology. janv, vol.140, issue.1, pp.124-155, 2011.

R. Loomba, M. Abraham, A. Unalp, L. Wilson, J. Lavine et al., Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis, Hepatology. sept, vol.56, issue.3, pp.943-51, 2012.

J. Bazick, M. Donithan, B. A. Neuschwander-tetri, D. Kleiner, E. M. Brunt et al., Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD, Diabetes Care. juill, vol.38, issue.7, pp.1347-55, 2015.

G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari et al., Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients, Diabetes Care. 1 mai, vol.30, issue.5, pp.1212-1220, 2007.

M. Hamaguchi, T. Kojima, N. Takeda, C. Nagata, J. Takeda et al., Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease, World J Gastroenterol. 14 mars, vol.13, issue.10, pp.1579-84, 2007.

Y. J. Zhou, Y. Y. Li, Y. Q. Nie, C. M. Huang, and C. Y. Cao, Natural course of nonalcoholic fatty liver disease in southern China: A prospective cohort study, Journal of Digestive Diseases, vol.13, issue.3, pp.153-60, 2012.

A. Mantovani, L. Mingolla, R. Rigolon, I. Pichiri, V. Cavalieri et al., Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes, International Journal of Cardiology. déc, vol.225, pp.387-91, 2016.

I. Zeb, D. Li, M. J. Budoff, R. Katz, L. et al., Nonalcoholic Fatty Liver Disease and Incident Cardiac Events: The Multi-Ethnic Study of Atherosclerosis, Journal of the American College of Cardiology. 26 avr, vol.67, issue.16, pp.1965-1971, 2016.

E. Bonora and G. Targher, Increased risk of cardiovascular disease and chronic kidney disease in NAFLD, Nat Rev Gastroenterol Hepatol, vol.8, issue.2012

R. Chinnadurai, C. Chrysochou, and P. A. Kalra, Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease, Nephron, vol.141, issue.1, pp.24-30, 2019.

A. Lonardo, S. Sookoian, C. J. Pirola, and G. Targher, Non-alcoholic fatty liver disease and risk of cardiovascular disease, Metabolism. 1 août, vol.65, issue.8, pp.1136-50, 2016.

R. Pais, P. Giral, J. Khan, D. Rosenbaum, C. Housset et al., Fatty liver is an independent predictor of early carotid atherosclerosis, Journal of Hepatology. juill, vol.65, issue.1, pp.95-102, 2016.

D. H. Sinn, D. Kang, Y. Chang, S. Ryu, S. Gu et al., Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study, Gut. févr, vol.66, issue.2, pp.323-332, 2017.

G. Targher, C. D. Byrne, A. Lonardo, G. Zoppini, and C. Barbui, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis, Journal of Hepatology. 1 sept, vol.65, issue.3, pp.589-600, 2016.

L. B. Vanwagner, H. Ning, C. E. Lewis, C. M. Shay, J. Wilkins et al., Associations between Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis in Middle-Aged Adults: The Coronary Artery Risk Development in Young Adults Study, Atherosclerosis. août, vol.235, issue.2, pp.599-605, 2014.

D. Viglino, A. Plazanet, S. Bailly, M. Benmerad, I. Jullian-desayes et al., Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease, vol.8, 2018.

H. Li, B. Hu, L. Wei, L. Zhou, L. Zhang et al., Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions, European Journal of Neurology. mars, vol.25, issue.3, pp.577-611, 2018.

M. Brett, C. , H. Thomas, M. , J. Christy et al., Modified National Institutes of Health Stroke Scale for Use in, Stroke Clinical Trials. Stroke. 1 mai, vol.33, issue.5, pp.1261-1267, 2002.

T. J. Quinn, K. Mcarthur, J. Dawson, M. R. Walters, and K. R. Lees, Reliability of structured modified rankin scale assessment, Stroke. déc, vol.41, issue.12, p.602, 2010.

F. Valbusa, D. Agnoletti, L. Scala, C. Grillo, P. Arduini et al., Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure, International Journal of Cardiology. 15 août, vol.265, pp.162-170, 2018.

T. G. Simon, K. E. Corey, C. P. Cannon, M. Blazing, J. Park et al., The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe, International Journal of Cardiology. 1 nov, vol.270, pp.245-52, 2018.

M. Baik, S. U. Kim, S. Kang, H. J. Park, H. S. Nam et al., Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients, Cerebrovascular Diseases, vol.47, issue.1, pp.32-41, 2019.

S. Mcpherson, T. Hardy, J. Dufour, S. Petta, M. Romero-gomez et al., Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis, Am J Gastroenterol. mai, vol.112, issue.5, pp.740-51, 2017.

D. C. Wikimedecine-;-goff, L. , D. M. Bennett, G. Coady, S. et al., ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Journal of the American College of Cardiology. 1 juill, vol.63, issue.25, pp.2935-59, 2013.

J. Boursier, J. Zarski, . Ledinghen-v-de, M. Rousselet, N. Sturm et al., Determination of reliability criteria for liver stiffness evaluation by transient elastography, Hepatology, vol.57, issue.3, pp.1182-91, 2013.

M. Lafitte, Y. Pucheu, K. Latry, M. Dijos, E. Casassus et al., Predictors of cardiovascular prognosis in patients receiving optimized secondary prevention measures after acute coronary syndrome, European Journal of Preventive Cardiology. avr, vol.20, issue.2, pp.283-90, 2013.

F. E. Harrell, K. L. Lee, and D. B. Mark, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med. 28 févr, vol.15, issue.4, pp.361-87, 1996.

G. Patti, I. Cavallari, F. Andreotti, P. Calabrò, P. Cirillo et al., Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucoselowering drugs, Nature Reviews Cardiology. févr, vol.16, issue.2, p.113, 2019.

E. Zengin, C. Bickel, R. B. Schnabel, T. Zeller, K. Lackner et al., Utility of the Framingham Risk Score in predicting secondary events in patients following percutaneous coronary intervention: A timetrend analysis, American Heart Journal. 1 févr, vol.8, issue.2015, pp.115-143, 2016.

S. C. Smith, E. J. Benjamin, R. O. Bonow, L. T. Braun, M. A. Creager et al., AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation, Circulation, vol.29, issue.22, pp.2458-73, 2011.

A. Bertola, T. Ciucci, D. Rousseau, V. Bourlier, C. Duffaut et al., Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients, Diabetes. sept, vol.61, issue.9, pp.2238-2285, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00726176

Z. Chen, R. Yu, Y. Xiong, F. Du, and S. Zhu, A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease, Lipids Health Dis, vol.16, issue.1, p.203, 2017.

C. E. Ndumele, K. Nasir, R. D. Conceiçao, J. Carvalho, R. S. Blumenthal et al., Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation, Arterioscler Thromb Vasc Biol. août, vol.31, issue.8, pp.1927-1959, 2011.

R. Russell, Atherosclerosis -An Inflammatory Disease, The New England Journal of Medicine, vol.12, 1999.

S. H. Moon, T. S. Noh, Y. S. Cho, S. P. Hong, S. H. Hyun et al., Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography, Angiology. mai, vol.66, issue.5, pp.472-80, 2015.

L. S. Bhatia, N. P. Curzen, P. C. Calder, and C. D. Byrne, Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?, Eur Heart J. 1 mai, vol.33, issue.10, pp.1190-200, 2012.

, Accident vasculaire cérébral (AVC) [Internet]. Inserm -La science pour la santé

D. Sur,

, Inserm -La science pour la santé

C. Corpechot, F. Carrat, A. Poujol-robert, F. Gaouar, D. Wendum et al., Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis, Hepatology, vol.56, issue.1, pp.198-208, 2012.

C. Corpechot, F. Gaouar, E. Naggar, A. Kemgang, A. Wendum et al., Baseline Values and Changes in Liver Stiffness Measured by Transient Elastography Are Associated With Severity of Fibrosis and Outcomes of Patients With Primary Sclerosing Cholangitis, Gastroenterology. avr, vol.146, issue.4, pp.970-979, 2014.

J. Vergniol, J. Boursier, C. Coutzac, S. Bertrais, J. Foucher et al., Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C, Hepatology, vol.60, issue.1, pp.65-76, 2014.

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs

, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré et méprisé si j'y manque